MUMBAI, India, Aug. 31 -- Intellectual Property India has published a patent application (202617081738 A) filed by Renagade Therapeutics; and Orna Therapeutics, Inc. on July 02, 2026, for Lipid Nanoparticles Comprising Coding Rna Molecules For Use In Gene Editing And As Vaccines And Therapeutic Agents.
Inventors include Jayaraman, Muthusamy; Sankaran, Ganapathy Subramanian No; Smith, David Townsend; Rhym, Luke Hyunsik; Narayanan, Elisabeth; John, Shinu Application Number; Wang, Yinghua; Kosakowska, Karolina Anna; Bolen, Joseph Number; Presnyak, Vladimir; and Pepin, Christopher Stephen.
The application for the patent was published on August 28, 2026, under issue no. 35/2026.
Abstract: The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.
Disclaimer: Curated by HT Syndication.
